主观认知下降向轻度认知障碍或痴呆进展与阿尔茨海默病生物标志物的关系:一项荟萃分析
该荟萃分析检索三个数据库至2021年5月7日,纳入8项研究,评估主观认知下降(SCD)人群中阿尔茨海默病(AD)生物标志物阳性与临床进展至轻度认知障碍(MCI)或痴呆的风险关联。结果显示,完整AD病理者进展风险显著升高(OR 11.36,95%CI 1.97-65.41),淀粉样病理仅阳性者OR 5.89(95%CI 2.33-14.90)。
要点
- SCD伴完整AD病理者进展至MCI或痴呆的风险升高(OR 11.36,95%CI 1.97-65.41)。
- 淀粉样病理仅阳性者进展风险亦升高(OR 5.89,95%CI 2.33-14.90)。
- 完整AD病理的阳性预测值为59.7%(95%CI 48.8%-69.3%),阴性预测值为89.4%(95%CI 86.7%-91.7%)。
核心结论
- 与无AD病理的SCD个体相比,伴完整AD病理的SCD个体进展为MCI或痴呆的风险大幅升高。
研究设计与样本
- 荟萃分析,检索PubMed、PsycINFO和Cochrane数据库自建库至2021年5月7日,最终纳入8项研究。
- 由2名研究者独立进行文献检索、数据收集和数据提取,遵循PRISMA和Cochrane指南。
- 采用随机效应荟萃分析汇总比值比(OR),并计算灵敏度、特异度、阳性预测值(PPV)、阴性预测值(NPV)和似然比。
- 主要结局为伴AD病理生物标志物的SCD个体相对于无AD病理生物标志物者进展至MCI或痴呆的OR。
主要发现
- 异常生物标志物患病率范围:淀粉样蛋白为15.6%至35.9%,磷酸化tau(p-tau)为11.1%至33.6%,总tau(t-tau)为12.3%至46.3%,完整AD病理(淀粉样病理伴p-tau或t-tau升高)为7.8%至24.4%。
- 临床进展风险在淀粉样病理仅阳性者中升高(OR 5.89,95%CI 2.33-14.90)。
- p-tau升高者临床进展风险升高(OR 3.99,95%CI 2.34-6.85)。
- t-tau升高者临床进展风险升高(OR 2.26,95%CI 1.14-4.48)。
- 完整AD病理者临床进展风险升高(OR 11.36,95%CI 1.97-65.41),其PPV为59.7%(95%CI 48.8%-69.3%),NPV为89.4%(95%CI 86.7%-91.7%);淀粉样病理仅阳性者PPV为28.2%(95%CI 23.7%-32.2%),NPV为94.9%(95%CI 93.4%-96.2%)。
关键数值与推荐
- 淀粉样病理仅阳性者进展至MCI或痴呆的OR为5.89(95%CI 2.33-14.90)。
- p-tau升高者进展至MCI或痴呆的OR为3.99(95%CI 2.34-6.85)。
- t-tau升高者进展至MCI或痴呆的OR为2.26(95%CI 1.14-4.48)。
- 完整AD病理者进展至MCI或痴呆的OR为11.36(95%CI 1.97-65.41)。
- 完整AD病理者PPV为59.7%(95%CI 48.8%-69.3%),NPV为89.4%(95%CI 86.7%-91.7%);淀粉样病理仅阳性者PPV为28.2%(95%CI 23.7%-32.2%),NPV为94.9%(95%CI 93.4%-96.2%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The risk of mild cognitive impairment (MCI) or dementia in individuals with subjective cognitive decline (SCD) and biomarkers indicating Alzheimer disease (AD) pathology in comparison with individuals with SCD without biomarker evidence for AD is critical to delineate the potential role of biomarker assessment in this group. We performed a meta-analysis of studies on this topic. METHODS: Three databases (PubMed, PsycINFO, and Cochrane) were searched from inception to May 7, 2021. Search strings included the terms: subjective cognitive decline, biomarker, amyloid, tau, risk, Alzheimer, mild cognitive impairment, and dementia. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane guidelines, 2 researchers independently performed literature search, data collection, and data extraction. We summarized odds ratios (ORs) in random-effects meta-analyses and calculated sensitivity, specificity, positive predictive values (PPVs) and negative predictive values (NPVs), and likelihood ratios. The primary outcome was the OR of progression from SCD to MCI or dementia in cases with biomarkers indicative of AD pathology relative to the chance of progression in cases with biomarkers indicating no AD pathology. RESULTS: Of 4,147 studies screened, 8 studies were selected. The risk of bias analysis revealed a low risk of bias in all studies. The prevalence of abnormal biomarkers ranged between 15.6% and 35.9% for amyloid, 11.1% and 33.6% for phosphorylated tau (p-tau), 12.3% and 46.3% for total tau (t-tau), and 7.8% and 24.4% for full AD pathology (amyloid pathology with either increased p-tau or t-tau). The chance of clinical progression was increased in cases of amyloid pathology only (OR 5.89, 95% CI 2.33-14.90), elevated p-tau (OR 3.99, 95% CI 2.34-6.85), elevated t-tau (OR 2.26, 95% CI 1.14-4.48), and full AD pathology (OR 11.36, 95% CI 1.97-65.41). The latter showed a PPV of 59.7% (95% CI 48.8%-69.3%) and an NPV of 89.4% (95% CI 86.7%-91.7%), whereas amyloid pathology only showed a PPV of 28.2% (95% CI 23.7%-32.2%) and an NPV of 94.9% (95% CI 93.4%-96.2%). DISCUSSION: Individuals with SCD and full AD pathology have a substantially increased risk of developing MCI or dementia in comparison with individuals with SCD without AD pathology. TRIAL REGISTRATION INFORMATION: PROSPERO CRD42020175282.
引用
- Rostamzadeh A, Bohr L, Wagner M, et al. Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-analysis. Neurology. 2022. PMID: 36028322. doi:10.1212/WNL.0000000000201072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。